Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin.

Krausz AE, Adler BL, Makdisi J, Schairer D, Rosen J, Landriscina A, Navati M, Alfieri A, Friedman JM, Nosanchuk JD, Rodriguez-Gabin A, Ye KQ, McDaid HM, Friedman AJ.

Precis Nanomed. 2018 Oct;1(3):173-182. doi: 10.33218/prnano1(3).181029.1. Epub 2018 Oct 27.

2.

Improved Dose-Response Relationship of (+)-Discodermolide-Taxol Hybrid Congeners.

Nadaradjane C, Yang CH, Rodriguez-Gabin A, Ye K, Sugasawa K, Atasoylu O, Smith AB 3rd, Horwitz SB, McDaid HM.

J Nat Prod. 2018 Mar 23;81(3):607-615. doi: 10.1021/acs.jnatprod.8b00111. Epub 2018 Mar 9.

3.

Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.

Andreopoulou E, Kelly CM, McDaid HM.

Breast Care (Basel). 2017 Mar;12(1):21-28. doi: 10.1159/000455821. Epub 2017 Feb 7. Review.

4.

A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC.

Samaraweera L, Adomako A, Rodriguez-Gabin A, McDaid HM.

Sci Rep. 2017 May 15;7(1):1900. doi: 10.1038/s41598-017-01964-1.

5.

Structural Basis of Microtubule Stabilization by Discodermolide.

Prota AE, Bargsten K, Redondo-Horcajo M, Smith AB 3rd, Yang CH, McDaid HM, Paterson I, Horwitz SB, Fernando Díaz J, Steinmetz MO.

Chembiochem. 2017 May 18;18(10):905-909. doi: 10.1002/cbic.201600696. Epub 2017 Mar 27.

6.

Correction: Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma.

Hou JY, Rodriguez-Gabin A, Samaraweera L, Hazan R, Goldberg GL, Horwitz SB, McDaid HM.

PLoS One. 2016 Mar 11;11(3):e0151750. doi: 10.1371/journal.pone.0151750. eCollection 2016. No abstract available.

7.

Therapies for triple negative breast cancer.

Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM.

Expert Opin Pharmacother. 2015 May;16(7):983-98. Review.

8.

N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties.

Qian X, Anzovino A, Kim S, Suyama K, Yao J, Hulit J, Agiostratidou G, Chandiramani N, McDaid HM, Nagi C, Cohen HW, Phillips GR, Norton L, Hazan RB.

Oncogene. 2014 Jun 26;33(26):3411-21. doi: 10.1038/onc.2013.310. Epub 2013 Aug 26.

9.

Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.

Hou JY, Rodriguez-Gabin A, Samaraweera L, Hazan R, Goldberg GL, Horwitz SB, McDaid HM.

PLoS One. 2013;8(2):e54103. doi: 10.1371/journal.pone.0054103. Epub 2013 Feb 4. Erratum in: PLoS One. 2016;11(3):e0151750. Samaweera, Leleesha [corrected to Samaraweera, Leleesha].

10.

High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.

Wang Y, Sparano JA, Fineberg S, Stead L, Sunkara J, Horwitz SB, McDaid HM.

Clin Breast Cancer. 2013 Apr;13(2):103-8. doi: 10.1016/j.clbc.2012.11.003. Epub 2012 Dec 6.

11.

Characterization of a human βV-tubulin antibody and expression of this isotype in normal and malignant human tissue.

Chao SK, Wang Y, Verdier-Pinard P, Yang CP, Liu L, Rodriguez-Gabin A, McDaid HM, Horwitz SB.

Cytoskeleton (Hoboken). 2012 Aug;69(8):566-76. doi: 10.1002/cm.21043. Epub 2012 Jul 2.

12.

Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence.

Chao SK, Horwitz SB, McDaid HM.

Oncotarget. 2011 Jan-Feb;2(1-2):89-98.

13.

Resistance to discodermolide, a microtubule-stabilizing agent and senescence inducer, is 4E-BP1-dependent.

Chao SK, Lin J, Brouwer-Visser J, Smith AB 3rd, Horwitz SB, McDaid HM.

Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):391-6. doi: 10.1073/pnas.1016962108. Epub 2010 Dec 20.

14.

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression.

Legrier ME, Yang CP, Yan HG, Lopez-Barcons L, Keller SM, Pérez-Soler R, Horwitz SB, McDaid HM.

Cancer Res. 2007 Dec 1;67(23):11300-8.

15.

Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone.

Mani S, McDaid HM, Grossman A, Muggia F, Goel S, Griffin T, Colevas D, Horwitz SB, Egorin MJ.

Ann Oncol. 2007 Jan;18(1):190-5. Epub 2006 Oct 3.

PMID:
17018704
16.

Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing mice.

Huang GS, Lopez-Barcons L, Freeze BS, Smith AB 3rd, Goldberg GL, Horwitz SB, McDaid HM.

Clin Cancer Res. 2006 Jan 1;12(1):298-304.

17.

Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.

McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Pérez-Soler R, Horwitz SB.

Cancer Res. 2005 Apr 1;65(7):2854-60.

18.

Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study.

McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB.

Clin Cancer Res. 2002 Jul;8(7):2035-43.

20.

Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines.

Martello LA, McDaid HM, Regl DL, Yang CP, Meng D, Pettus TR, Kaufman MD, Arimoto H, Danishefsky SJ, Smith AB 3rd, Horwitz SB.

Clin Cancer Res. 2000 May;6(5):1978-87.

21.

Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines.

McDaid HM, Bhattacharya SK, Chen XT, He L, Shen HJ, Gutteridge CE, Horwitz SB, Danishefsky SJ.

Cancer Chemother Pharmacol. 1999;44(2):131-7.

PMID:
10412947
22.

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer.

McDaid HM, Cairns MT, Atkinson RJ, McAleer S, Harkin DP, Gilmore P, Johnston PG.

Br J Cancer. 1999 Feb;79(5-6):933-9.

Supplemental Content

Loading ...
Support Center